<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003712</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000066820</org_study_id>
    <secondary_id>P30CA054174</secondary_id>
    <secondary_id>UTHSC-9785011303</secondary_id>
    <secondary_id>SACI-IDD-98-02</secondary_id>
    <secondary_id>W-AR-3066K1-100-US</secondary_id>
    <secondary_id>NCI-V98-1506</secondary_id>
    <nct_id>NCT00003712</nct_id>
  </id_info>
  <brief_title>CCI-779 in Treating Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous CCI-779 Given Once Daily for 5 Days Every 2 Weeks to Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center at San Antonio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Texas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center at San Antonio</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of CCI-779 in treating patients who have&#xD;
      advanced solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the safety, tolerability, and maximum tolerated dose (MTD) of CCI-779 in&#xD;
           patients with advanced solid tumors (part I) who are not receiving anticonvulsant&#xD;
           therapy.&#xD;
&#xD;
        -  Determine the safety, tolerability, and MTD in patients with recurrent gliomas or brain&#xD;
           metastases (part II) who are receiving anticonvulsant therapy.&#xD;
&#xD;
        -  Determine the preliminary pharmacokinetic profile and antitumor activity of CCI-779 in&#xD;
           these patients.&#xD;
&#xD;
      OUTLINE: This is an open-label, dose-escalation study.&#xD;
&#xD;
        -  Part I: Patients receive CCI-779 IV over 30 minutes on days 1-5, followed by a 9 day&#xD;
           rest period. Treatment courses repeat every 2 weeks in the absence of disease&#xD;
           progression or unacceptable toxicity.&#xD;
&#xD;
      The maximum tolerated dose for part I is defined as the dose level at which 33% of patients&#xD;
      experience dose limiting toxicity.&#xD;
&#xD;
        -  Part II: Patients receive the same treatment schedule as part I. Three patients with CNS&#xD;
           tumors are entered at the dose of CCI-779 determined to be the MTD in Part I. At least 3&#xD;
           patients are entered at each dose level in part II.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 20 patients will be accrued for part I for this study within&#xD;
      8 months, and 12 patients will be accrued for part II within 7 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2001</start_date>
  <completion_date type="Actual">June 2002</completion_date>
  <primary_completion_date type="Actual">June 2002</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Actual">15</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <condition>Metastatic Cancer</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temsirolimus</intervention_name>
    <description>•Part I: Patients receive CCI-779 IV over 30 minutes on days 1-5, followed by a 9 day rest period. Treatment courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.&#xD;
The maximum tolerated dose for part I is defined as the dose level at which 33% of patients experience dose limiting toxicity.&#xD;
•Part II: Patients receive the same treatment schedule as part I. Three patients with CNS tumors are entered at the dose of CCI-779 determined to be the MTD in Part I. At least 3 patients are entered at each dose level in part II.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
        Part I:&#xD;
&#xD;
          -  Histologically proven advanced solid tumors that are refractory or for which no&#xD;
             curative therapy exists&#xD;
&#xD;
          -  No CNS metastases, peritumoral edema, or symptomatic brain metastases (part I)&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
        Part II:&#xD;
&#xD;
          -  Histologically proven recurrent gliomas or brain metastases for which no curative&#xD;
             therapy exists&#xD;
&#xD;
          -  Receiving anticonvulsants&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 9 g/dL&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin less than 1.5 mg/dL&#xD;
&#xD;
          -  AST or ALT less than 3 times upper limit of normal (ULN) (less than 5 times ULN if&#xD;
             liver metastases)&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine less than 2 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No unstable angina&#xD;
&#xD;
          -  No myocardial infarction within past 6 months&#xD;
&#xD;
          -  No maintenance therapy for life-threatening arrhythmias&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No active infection or other serious concurrent illness&#xD;
&#xD;
          -  Triglycerides no greater than 300 mg/dL&#xD;
&#xD;
          -  Cholesterol no greater than 350 mg/dL&#xD;
&#xD;
          -  No known hypersensitivity to macrolide antibiotics (e.g., clarithromycin,&#xD;
             erythromycin, or azithromycin)&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 3 weeks since prior chemotherapy (6 weeks since nitrosoureas and mitomycin)&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Concurrent corticosteroids used to reduce edema in patients with primary or metastatic&#xD;
             CNS tumors allowed&#xD;
&#xD;
          -  No concurrent hormonal therapy&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 3 weeks since prior radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 1 month since prior investigational agents&#xD;
&#xD;
          -  At least 3 weeks since prior immunosuppressive therapy&#xD;
&#xD;
          -  No concurrent anticonvulsant therapy (part I)&#xD;
&#xD;
          -  No concurrent immunosuppressive therapy (e.g., terfenadine, cisapride, astemizole,&#xD;
             pimozide)&#xD;
&#xD;
          -  No known agents that inhibit or induce cytochrome p450&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric K. Rowinsky, MD</last_name>
    <role>Study Chair</role>
    <affiliation>San Antonio Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic Cancer Center</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Antonio Cancer Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229-3264</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>July 14, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2003</study_first_posted>
  <last_update_submitted>August 7, 2012</last_update_submitted>
  <last_update_submitted_qc>August 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 9, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent adult brain tumor</keyword>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <keyword>tumors metastatic to brain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

